{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-075030","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.248825+00:00","generated_at":"2026-06-21T13:05:22.941150+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revelation Biosciences receives Nasdaq delisting notice; trading to be suspended Dec 2, 2022","bullets":["Received second Nasdaq deficiency letter on Nov 23, 2022 for failing $2.5M stockholders' equity requirement.","As of Sept 30, 2022, stockholders' equity was $2,227,768, below the minimum.","Trading suspension scheduled for Dec 2, 2022 unless appeal is filed.","Company intends to request hearing before an independent panel to stay suspension.","No immediate effect on trading of units, common stock or warrants under REVBU, REVB, REVBW."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-075030","json":"https://secwatch.observer/filing/0001213900-22-075030.json","markdown":"https://secwatch.observer/filing/0001213900-22-075030.md","text":"https://secwatch.observer/filing/0001213900-22-075030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/ea169284-8k_revelation.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:05:22.941150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"397346bf70de9df4a84a883ee9f9eb999413c7be","claim":"REVELATION BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"While the Company did complete a $5 million offering in July 2022, in the Form 10-Q for the quarter ended September 30,2022 the Company reported a stockholders’ equity of $2,227,768, less than the Stockholders’ Equity Requirement. As a result, on November 23, 2022, the Company received a further deficiency letter (the “Second Nasdaq Letter”). The Second Nasdaq","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"5bc6793982021f89a3c9faee5320e0d974857ccf","claim":"REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"Equity Requirement was based on the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, reporting the stockholders’ deficit of $98,511. Pursuant to the First Nasdaq Letter, the Company submitted a plan to regain compliance and the Company which contemplated capital raises of $10 million, following which Nasdaq","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390022075030/0001213900-22-075030-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}